1. Home
  2. AUPH vs CLB Comparison

AUPH vs CLB Comparison

Compare AUPH & CLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • CLB
  • Stock Information
  • Founded
  • AUPH 1993
  • CLB 1936
  • Country
  • AUPH Canada
  • CLB United States
  • Employees
  • AUPH N/A
  • CLB N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • CLB
  • Sector
  • AUPH Health Care
  • CLB
  • Exchange
  • AUPH Nasdaq
  • CLB Nasdaq
  • Market Cap
  • AUPH 1.1B
  • CLB 553.2M
  • IPO Year
  • AUPH 1999
  • CLB 1995
  • Fundamental
  • Price
  • AUPH $7.58
  • CLB $12.79
  • Analyst Decision
  • AUPH Strong Buy
  • CLB Hold
  • Analyst Count
  • AUPH 2
  • CLB 4
  • Target Price
  • AUPH $11.50
  • CLB $15.00
  • AVG Volume (30 Days)
  • AUPH 1.6M
  • CLB 594.8K
  • Earning Date
  • AUPH 07-31-2025
  • CLB 07-23-2025
  • Dividend Yield
  • AUPH N/A
  • CLB 0.31%
  • EPS Growth
  • AUPH N/A
  • CLB N/A
  • EPS
  • AUPH 0.27
  • CLB 0.59
  • Revenue
  • AUPH $247,295,000.00
  • CLB $517,796,000.00
  • Revenue This Year
  • AUPH $12.15
  • CLB N/A
  • Revenue Next Year
  • AUPH $18.31
  • CLB $2.92
  • P/E Ratio
  • AUPH $28.53
  • CLB $21.69
  • Revenue Growth
  • AUPH 29.20
  • CLB 1.32
  • 52 Week Low
  • AUPH $5.20
  • CLB $10.15
  • 52 Week High
  • AUPH $10.67
  • CLB $25.13
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 40.36
  • CLB 60.39
  • Support Level
  • AUPH $7.29
  • CLB $11.28
  • Resistance Level
  • AUPH $8.86
  • CLB $12.98
  • Average True Range (ATR)
  • AUPH 0.34
  • CLB 0.57
  • MACD
  • AUPH -0.06
  • CLB 0.09
  • Stochastic Oscillator
  • AUPH 19.37
  • CLB 85.31

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

Share on Social Networks: